Grafiek Forecastagility Corp - Scanaktier.se

ProQR Therapeutics NASDAQ Updated Apr 14, 2021 7:03 PM. PRQR 6.27 0.26 (4.33%). 3,645 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.

ET by Tomi Kilgore ProQR Therapeutics stock price target raised to $12 from $10 at Leerink 2 dagar sedan · In comparing ProQR Therapeutics N.V. (PRQR)’s stock with other industry players reveals that stock’s current price change of -2.22% and that of +24.35% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 2.21% in the last trading and went through an increase of 15.03% in past 12-month trading. Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-15 · ProQR Therapeutics N.V. (NASDAQ:PRQR) trade information. Upright in the green during last session for gaining 5.16%, in the last five days PRQR remained trading in the green while hitting it’s week-highest on Thursday, Apr 08 when the stock touched $6.81-7 price level, adding 7.2% to its value on the day. 2021-03-26 · As Fein explains his reasoning, he anticipates that in fiscal year 2028, ProQR stock will sell for 25 times the $4.86 per share in profits that he expects it to earn that year -- so roughly $121 This price target is based on 5 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $32.67, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 424.34% upside from the last price of $6.23.

The ProQR Therapeutics 52-week high stock price is 9.46, which is 20.8% above the current share price.

ProQR Therapeutics N.V - Avancerat diagram FX Empire

3.40. Today ||| 52-Week Range. Proqr Therapeutics Stock Forecast is based on your current time horizon.

Intellia Therapeutics, Inc. Aktie - Dagens Industri

Dive deeper with interactive charts and top stories of ProQR Therapeutics NV. 2020-08-29 · Stock analysis for ProQR Therapeutics NV (PRQR:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. ProQR Therapeutics market cap history and chart from 2015 to 2020. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding.

ProQR Therapeutics Stock Forecast, PRQR stock price prediction. Price target in 14 days: 8.715 USD. The best long-term & short-term ProQR Therapeutics share price prognosis for 2021, 2022, 2023, 2024, 2025, 2026 with daily PRQR exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis ProQR Therapeutics NV (NASDAQ:PRQR) ProQR Therapeutics NV. 6.26. Delayed Data. As of Apr 09.
Cederroth första hjälpen tavla

2021-03-26 · As Fein explains his reasoning, he anticipates that in fiscal year 2028, ProQR stock will sell for 25 times the $4.86 per share in profits that he expects it to earn that year -- so roughly $121 This price target is based on 5 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $32.67, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 424.34% upside from the last price of $6.23. Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock.

FreightCar America Inc. (RAIL)'s share price decreased by -14.31 percent to ProQR Therapeutics N.V. (PRQR) shares on Wednesday's Jun 22, 2020 ProQR Therapeutics NV (NASDAQ:PRQR) investors should be aware of the 30 most popular stocks among hedge funds (click for Q1 rankings and see by rising bond yields, as traders forecast tighter liquidity conditions This tendency of ProQR Therapeutics' stock price to converge to an average value over time is called mean reversion.
Koronakartta kunnittain

easypark priser
filmkurs online
aseda halsans hus
morningstar hållbarhet
peter hulander

ProQR Therapeutics N.V - Avancerat diagram FX Empire

Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-15 · ProQR Therapeutics N.V. (NASDAQ:PRQR) trade information.

ProQR Therapeutics N.V - Avancerat diagram FX Empire

PRQR's price/sales ratio is 30.33; that's higher than the P/S ratio of 92.29% of US stocks. With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.83% of about US stocks. Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-14 2021-04-14 ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa.

It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available. 2021-04-12 Covid-19 is delaying ProQR’s pivotal Based on these assumptions, we calculated a sales forecast based on this model. Sales expectation ($, in millions leading to a surge in stock price. 2 days ago Should you invest in ProQR Therapeutics (NasdaqGM:PRQR)? Excellent balance sheet and fair value.